title: Clinical presentation and prognosis of the 2009 H1N1 influenza A infection in HIV-1-infected patients: a Spanish multicenter study.
abstract: OBJECTIVE
  The aim of the study was to describe the clinical presentation and prognosis in HIV-1-infected patients with hospital admission and pandemic influenza A 2009 (H1N1) confirmed, and compare this data with those of a general population.
  
  
  METHODS
  : This is a prospective study in nature.
  
  
  METHODS
  All adult patients admitted to 13 hospitals in Spain with confirmed influenza A 2009(H1N1) virus infection by real-time reverse transcriptase PCR assay or culture from June 12 to November 10, 2009 were recruited and followed up until 1 month after discharge. In the HIV group risk factors for HIV infection, AIDS criteria, last CD4 cell count and viral load, and antiretroviral therapy and pneumococcal vaccines were collected.
  
  
  RESULTS
  Five hundred and eighty-five patients were recruited, 26 with HIV-1 infection and 559 non-HIV. The HIV patients had a long-term well controlled infection with a median CD4 cell count 503 cells/μl and 84% with undetectable viral load, although more frequently they had chronic liver and chronic obstructive pulmonary disease. No significant differences were observed about reported symptoms and physical findings on hospital admission. About 50% of patients in both groups present radiological infiltrates and 30% present respiratory failures. Practically all the patients in both groups received influenza antiviral therapy and in each group 80% received antibacterial therapy. No differences were observed in clinical outcomes.
  
  
  CONCLUSIONS
  In HIV patients, well controlled on HAART, the pandemic influenza virus AH1N1 had a similar clinical outcome and prognosis to that of non-HIV patients.
authors.affiliation: Palma De Mallorca, Hospital Son Dureta, Spain. melchor.riera@ssib.es
authors.forename: Melchor
authors.initials: M
authors.lastname: Riera
authors.forename: Antoni
authors.initials: A
authors.lastname: Payeras
authors.forename: Maria A
authors.initials: MA
authors.lastname: Marcos
authors.forename: Diego
authors.initials: D
authors.lastname: Viasus
authors.forename: Maria C
authors.initials: MC
authors.lastname: Farinas
authors.forename: Ferran
authors.initials: F
authors.lastname: Segura
authors.forename: Julian
authors.initials: J
authors.lastname: Torre-Cisneros
authors.forename: Alejandro
authors.initials: A
authors.lastname: Martín-Quirós
authors.forename: Jesús
authors.initials: J
authors.lastname: Rodríguez-Baño
authors.forename: Juan
authors.initials: J
authors.lastname: Vila
authors.forename: Elisa
authors.initials: E
authors.lastname: Cordero
authors.forename: Jordi
authors.initials: J
authors.lastname: Carratalà
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D015497:HIV-1 / Q000276:immunology*; D006760:Hospitalization / Q000706:statistics & numerical data*; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology* / Q000472:pathogenicity; D007252:Influenza Vaccines; D007251:Influenza, Human / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D008297:Male; D011379:Prognosis; D011446:Prospective Studies; D013030:Spain / Q000453:epidemiology; D019562:Viral Load / Q000276:immunology
chemical_list: D007252:Influenza Vaccines